These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 17963857)

  • 1. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents.
    Sabatini R; Orsini G; Cagiano R; Loverro G
    Contraception; 2007 Nov; 76(5):342-7. PubMed ID: 17963857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study.
    Schramm G; Heckes B
    Contraception; 2007 Aug; 76(2):84-90. PubMed ID: 17656175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of efficacy, safety and effects on symptoms of androgenization of a generic oral contraceptive containing chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg.
    Hadji P; Biskup J; Boekhoff J; Ziller M; Bonn M; Rovati L
    Contraception; 2012 Oct; 86(4):359-65. PubMed ID: 22445436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belara--a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea.
    Zahradnik HP
    Eur J Contracept Reprod Health Care; 2005; 10 Suppl 1():12-8. PubMed ID: 16356877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups: an open-label, single-centre, phase IV study.
    Kerscher M; Reuther T; Bayrhammer J; Schramm G
    Clin Drug Investig; 2008; 28(11):703-11. PubMed ID: 18840013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of two estroprogestins containing ethynilestradiol 30 microg and drospirenone 3 mg and ethynilestradiol 30 microg and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations.
    Lello S; Primavera G; Colonna L; Vittori G; Guardianelli F; Sorge R; Raskovic D
    Gynecol Endocrinol; 2008 Dec; 24(12):718-23. PubMed ID: 19172543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belara--proven benefits in daily practice.
    Bitzer J
    Eur J Contracept Reprod Health Care; 2005; 10 Suppl 1():19-25. PubMed ID: 16356878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial.
    Plewig G; Cunliffe WJ; Binder N; Höschen K
    Contraception; 2009 Jul; 80(1):25-33. PubMed ID: 19501212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study.
    Anthuber S; Schramm GA; Heskamp ML
    Clin Drug Investig; 2010; 30(4):211-20. PubMed ID: 20225905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of an oral contraceptive containing chlormadinone acetate: results of a pooled analysis of noninterventional trials in adult and adolescent women.
    Schramm GA; Schrah G
    Contraception; 2011 Oct; 84(4):390-401. PubMed ID: 21920195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of oral contraceptives containing estradiol and nomegestrol acetate or ethinyl-estradiol and chlormadinone acetate on primary dysmenorrhea.
    Grandi G; Napolitano A; Xholli A; Tirelli A; Di Carlo C; Cagnacci A
    Gynecol Endocrinol; 2015 Oct; 31(10):774-8. PubMed ID: 26291811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in hormonal therapy for acne.
    Tan JK
    Skin Therapy Lett; 2007 Sep; 12(7):1-3. PubMed ID: 17940710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada.
    Endrikat JS; Milchev NP; Kapamadzija A; Georgievska J; Gerlinger C; Schmidt W; Feroze S
    Contraception; 2009 Jun; 79(6):428-32. PubMed ID: 19442777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects.
    Foidart JM
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():25-33. PubMed ID: 11246599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YAZ and the novel progestin drospirenone.
    Mishell DR
    J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone.
    Dickerson V
    J Reprod Med; 2002 Nov; 47(11 Suppl):985-93. PubMed ID: 12497673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent innovations in oral contraception.
    Cremer M; Phan-Weston S; Jacobs A
    Semin Reprod Med; 2010 Mar; 28(2):140-6. PubMed ID: 20391327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal contraceptives for acne management.
    Rich P
    Cutis; 2008 Jan; 81(1 Suppl):13-8. PubMed ID: 18338653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
    Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
    Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.